Global Vision Biotech marijuana Clinical Trials Anticipated for Cancer.
- Date: 06/08/19
- Author: Daniel Mathers
- Team: Global Vision Biotechnologies - Press Team
A flavonoid of marijuana – FBL-03G is anticipated to lead clinical trials with humans for treating pancreatic cancer with marijuana within the next few months, following the successful demonstration of its therapeutic efficacy in tumour progression in animals with pancreatic cancer. FBL-03G – has been derived from an endemic strain of marijuana Sativa found in Jamaica.
Global Vision Biotechnologies research team stated, “The world requires and demands a new standard of care that is both effective and novel for the treatment of this disease. As a recognised leader in this field of drug discovery, we are poised to bring this new standard of care to the world.”
The Global Vision Biotech research team developed a proprietary synthesis of the bioactive material, which is now available in commercial quantities for use in human clinical studies. The drug delivery payload has been designed to utilise a nano-drone delivery technology developed by Harvard Medical School for which protocol has been approved by the FDA.
The Orphan designation was passed into law by President Ronald Reagan, as the Orphan Drug Act of 1983, to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
The designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer US patients annually and that are expected to provide significant therapeutic advantage over existing treatments.